Navigation Links
Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated

- Findings Support Continued Development for Chronic Pain and Non-Pain

Indications -

LA JOLLA, Calif., Feb. 5 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data from its multiple dose clinical trial of tezampanel, an antagonist of the AMPA and kainate subgroup of glutamate receptors, show that the product candidate is safe and well-tolerated in normal male and female subjects.

These Phase I results support the company's continued development of tezampanel as a novel therapeutic for chronic pain and expand its potential therapeutic applications across a variety of persistent conditions in which activation of glutamate receptors initiates or sustains pathophysiological processes. These conditions include cancer pain and neuropathic pain, as well as non-pain conditions such as epilepsy, muscle spasticity and rigidity, and Parkinson's disease. A recently completed Phase IIb clinical trial of tezampanel in 306 patients with migraine met its primary endpoint for pain relief at two hours using a single 40 mg subcutaneous dose. In five previously conducted placebo-controlled, Phase II trials, an intravenous formulation of tezampanel demonstrated analgesic effect across all five studies using a variety of chronic pain models.

The Phase I double-blind, placebo-controlled trial enrolled 30 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily subcutaneous injections of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, tezampanel was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

"This study is an important step forward in the clinical development of tezampanel. Our ability to safely deliver multiple doses of tezampanel means that we can now pursue virtually any indication that requires chronic dosing," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "There is an emerging appreciation of the pathological effects of increased AMPA and kainate receptor activation by glutamate. By blocking both receptors, tezampanel and its oral prodrug, NGX426, may represent a unique and effective approach to treat a variety of chronic pain as well as non-pain conditions."

Tezampanel is the first AMPA/kainate antagonist to be studied in clinical trials for chronic pain. Both tezampanel and NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple chronic pain conditions. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. For example, during a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches. The blockade of similar receptors in other regions of the brain or spinal cord has been shown in animal models to attenuate pathophysiological processes such as the muscle spasticity and rigidity that occurs following stroke and spinal cord injury, or that may be associated with multiple sclerosis.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small molecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential for tezampanel as a treatment for migraine, the potential for NGX426 as a treatment for migraine, the potential for tezampanel to offer a unique approach to the management of pain, the potential for tezampanel or NGX426 to offer a unique approach to the management of pain and the potential timing, development and initiation of future clinical trials of tezampanel and NGX426. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether the results of the Phase I trial are predictive of results in subsequent trials of tezampanel or NGX426, whether further testing of tezampanel and NGX426 will result in data sufficient to support regulatory approval, whether AMPA/kainate antagonists will prove to be safe and effective treatments for migraine and other pain conditions as well as non-pain conditions, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its product candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics annual report on Form 10-K for the year ended Dec. 31, 2006, as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact:

Ev Graham

TorreyPines Therapeutics, Inc.

858-623-5665, x118

Media Contact:

David Schull

Russo Partners, LLC


Investor Contact:

Rhonda Chiger

Rx Communications


Investor Contact:

John Baldissera

BPC Financial Marketing


SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
4. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. (NASDAQ: ... on gastrointestinal and cardio-renal diseases, today announced that ... tenapanor, will be presented at the 2015 American ... will include measures of sustained response in IBS-C ... placebo-controlled, randomized Phase 2 trial. The meeting will ...
(Date:10/8/2015)... 2015  Trovagene, Inc., (NASDAQ:   TROV) a ... presentation of results from a field experience analysis ... SM (PCM) platform to accurately identify mutational ... determine appropriate therapy for patients. Mark Erlander ... delivering the results today in an oral presentation ...
(Date:10/8/2015)... 2015  Following months of investigation, Ross Feller Casey ... alleging that the anticoagulant Xarelto,s recommended dosage doesn,t work for ... Philadelphia on behalf of a ... the drug didn,t work as the manufacturer suggested. Ross ... shortly on behalf of clients from across the country with ...
Breaking Medicine Technology:
... CLARA, Calif., Oct. 7, 2011 ProteinSimple today ... and field service support for its biologics products ... product lines are included in this expanded support ... Micro-Flow Imaging systems. The biologics market ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, October 20, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, October ... webcast, please visit Cepheid,s website at at ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... The sixth annual cost of cybercrime study the Ponemon Institute released this ... The New York Times broke down some of those numbers in this article ... the companies surveyed, it only proves that regular threat assessments, penetration testing and emergency ...
(Date:10/10/2015)... ... ... Story Chaser is a one-of-a-kind app that makes reading fun while helping children ... words drop down and users tap the corresponding word. By answering correctly player earn ... making it a more engaging game. Users can use what are called Reading Powers ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, ... Place To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The ... up with a celebratory gala on October 1st. , Many of the features ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... the Pacific Associate Dean for Graduate Medical Education J. Michael Finley, DO, as ... Award. Finley was selected for his impact on graduate medical education opportunities for ...
Breaking Medicine News(10 mins):
... CardioCareLive, the world,s largest live online cardiology congress ... Medicine, today announced three new complimentary Continuing Medical ... days on Tuesday June 28th and Wednesday June ... and internal medicine and family care physicians in ...
... latest episode in the American Chemical Society,s (ACS) ... focuses on new blood test that can quickly ... bacterium that,s become a global threat, significantly improving ... Staphylococcus aureus, or simply MRSA. The podcast explains ...
... 24 (HealthDay News) -- Rain-making bacteria may shed some ... the Earth,s precipitation cycle, new research shows. ... meeting of the American Society for Microbiology in New ... of hailstones, suggesting that airborne microorganisms may trigger precipitation, ...
... knowledge of tuberculosisas well as in the practices, programs ... with human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) ... community. Research in the June issue of The ... use of 18F-FDG positron emission tomography (PET) scans can ...
... MA Electronic medical records (EMRs) have been in use ... utilization in recent years, due in part to research supporting ... become a standard in medical care, there is a need ... be refined. A group of researchers from Brigham and Women,s ...
... you may want to think twice before shooting hundreds of ... study from MIT neuroscientists shows that the most memorable photos ... and human-scale objects. Landscapes? They may be beautiful, but they ... are not the same," says MIT graduate student Phillip Isola, ...
Cached Medicine News:
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...
... The operating table MARS Enduro ... examinations or interventions are required before, ... Due to the motorised longitudinal adjustment ... provides optimum working conditions in examination, ...
... Exclusive, 210° Top Rotation provides uncommon ... surgery. The Hercules 6700B eliminates any ... head-end procedures, while providing ample leg ... sit during procedures. Removable back and ...
Medicine Products: